PMGC Holdings (ELAB) Accounts Payables (2022 - 2026)
PMGC Holdings (ELAB) posted Accounts Payables of $657006.0 for Q1 2026, down 5.82% sequentially from $697633.0 in Q4 2025, and up 70.91% YoY from $384418.0 in Q1 2025.
PMGC Holdings (ELAB) Accounts Payables (2022 - 2026) Analysis & Trends
PMGC Holdings has reported Accounts Payables for 5 years, with the latest figure at $657006.0 in Q1 2026.
- Quarterly Accounts Payables rose 70.91% year-over-year to $657006.0 in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $657006.0 (up 70.91% YoY) and the FY2025 annual result came in at $697633.0, up 45.04% from the prior year.
- Accounts Payables declined to $657006.0 in Q1 2026 per ELAB's latest filing, from $697633.0 in the prior quarter.
- Over five years, Accounts Payables peaked at $705.6 million in Q3 2023 and troughed at $134014.0 in Q4 2023.
- A 5-year average of $59.3 million and a median of $517440.0 in 2024 frame the typical range for Accounts Payables.
- The widest YoY moves for Accounts Payables: up 258.92% in 2024, down 99.83% in 2024.
- Over 5 years, Accounts Payables stood at $244704.0 in 2022, then slumped by 45.23% to $134014.0 in 2023, then soared by 258.92% to $481001.0 in 2024, then surged by 45.04% to $697633.0 in 2025, then slipped by 5.82% to $657006.0 in 2026.
- According to Business Quant data, Accounts Payables over the past three periods registered $657006.0, $697633.0, and $553879.0 for Q1 2026, Q4 2025, and Q3 2025 respectively.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Accounts Payables (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn | 429.50 Mn |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn | 1.16 Bn |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn | 1.52 Bn |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn | 167.00 Mn |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn | 470.30 Mn |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn | 108.02 Mn |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn | 622.65 Mn |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn | 428.93 Mn |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - | 35.57 Mn |
| 10 | PMGC Holdings | 31.22 Mn | 12.43 Mn | 385,691.00 | 1.27 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 657,006.00 |
| Dec 31, 2025 | 697,633.00 |
| Sep 30, 2025 | 553,879.00 |
| Jun 30, 2025 | 271,567.00 |
| Mar 31, 2025 | 384,418.00 |
| Dec 31, 2024 | 481,001.00 |
| Sep 30, 2024 | 1.22 Mn |
| Jun 30, 2024 | 1.18 Mn |
| Mar 31, 2024 | 395,249.00 |
| Dec 31, 2023 | 134,014.00 |
| Sep 30, 2023 | 705.63 Mn |
| Dec 31, 2022 | 244,704.00 |